ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1848

Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission

Ivan Arias de la Rosa1, Inmaculada Concepcion Aranda-Valera2, Rosa Roldan2, Maria Carmen Abalos-Aguilera1, Maria Dolores de la Rosa-Garrido2, Yolanda Jiménez-Gómez3, Carlos Perez-Sanchez3, Alejandro Escudero-Contreras1, Chary Lopez-Pedrera2, Eduardo Collantes-Estévez3 and Nuria Barbarroja3, 1Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adipocytokines, Atherosclerosis, Cardiovascular disease, inflammation and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the more common chronic diseases of childhood that often persists into adulthood and can result in significant long-term morbidity. Cardiovascular disease (CVD) is an important cause of mortality and morbidity in patients with rheumatoid arthritis and possibly other forms of adult inflammatory arthritis. However, the long-term risk of CVD for individuals with JIA remains uncertain Objective: To determine whether adults with JIA in remission and medium-long duration of the disease have an increased risk of CVD.

Methods: This is a cross-sectional study including 27 patients diagnosed with JIA according to the International League of Associations for Rheumatology criteria (ILAR 2001) were compared to 27 age- and sex-matched controls. Remission was determined by JADAS27<1 and according to Wallace criteria. An extensive clinical analysis including body index mass, lipid profile, HOMA-IR and intra-arterial blood pressure was performed. Intima media thickness of the common carotid artery (CIMT) was measured as a marker of subclinical atherosclerosis. Proinflammatory cytokines (TNFa, IL1b and IL6), molecules involved in endothelial dysfunction (VEGF, ICAM-1 and E-Selectin) and adipokines (leptin, adiponectin, resistin and visfatin) were analyzed on serum by ELISA

Results: Mean duration of the disease was 14.51 ± 2.20 years. Mean age was 29.31 ± 0.78. Time in remission was 4.22±0.64 years. Metabolic comordibities such as obesity and metabolic syndrome were more prevalent in our cohort of JIA patients compared to controls. Levels of cholesterol were significantly elevated in patients. CIMT was higher in JIA patients compared to controls, although it did not reach the statistical significance. Serum levels of cytokines (TNFa, IL6 and IL1b) and endothelial activation markers (VEGF and ICAM-1) were elevated in JIA adult patients. Serum levels of adiponectin were significantly decreased. In contrast, levels of resistin and visfatin were higher in JIA patients. Disease duration significantly correlated with CIMT values, cholesterol and TNFa levels. In addition, there was an association among levels of lipids, adipokines and inflammatory mediators.

Conclusion: In adult JIA patients with clinical remission, CMIT and levels of inflammatory cytokines, adipokines and endothelial activation markers were elevated, molecules with a relevant role in the onset and progression of endothelial dysfunction and atherosclerosis. These results might suggest that long-term JIA patients could have higher cardiovascular risk, although they are in sustained remission. Thus, cardiovascular risk assessment should be considered as part of routine clinical care in those patients.


Disclosure: I. Arias de la Rosa, None; I. C. Aranda-Valera, None; R. Roldan, None; M. C. Abalos-Aguilera, None; M. D. de la Rosa-Garrido, None; Y. Jiménez-Gómez, None; C. Perez-Sanchez, None; A. Escudero-Contreras, None; C. Lopez-Pedrera, None; E. Collantes-Estévez, None; N. Barbarroja, None.

To cite this abstract in AMA style:

Arias de la Rosa I, Aranda-Valera IC, Roldan R, Abalos-Aguilera MC, de la Rosa-Garrido MD, Jiménez-Gómez Y, Perez-Sanchez C, Escudero-Contreras A, Lopez-Pedrera C, Collantes-Estévez E, Barbarroja N. Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-risk-factors-in-adults-with-juvenile-idiopathic-arthritis-in-sustained-remission/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-factors-in-adults-with-juvenile-idiopathic-arthritis-in-sustained-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology